MET Inhibitors for the Treatment of Gastric Cancer: What’s Their Potential?
Haidar El Darsa,1 Rola El Sayed,2 Omar Abdel-Rahman1 1Division of Medical Oncology, Department of Oncology, Cross Cancer Institute, University of Alberta, Edmonton, Alberta, Canada; 2Division of Hematology-Oncology, Department of Internal Medicine, American University of Beirut Medical Center, Beiru...
Saved in:
Main Authors: | El Darsa H (Author), El Sayed R (Author), Abdel-Rahman O (Author) |
---|---|
Format: | Book |
Published: |
Dove Medical Press,
2020-10-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Critical evaluation of ramucirumab in the treatment of advanced gastric and gastroesophageal cancers
by: ElHalawani H, et al.
Published: (2015) -
Overexpression of PI3K p110α contributes to acquired resistance to MET inhibitor, in MET-amplified SNU-5 gastric xenografts
by: Ji F, et al.
Published: (2015) -
MET Inhibitor is Expected to Overcome MET Amplification-Induced Immunotherapy Resistance in Non-Small Cell Lung Cancer
by: Ji Ruan
Published: (2021) -
LRRK2 inhibitors and their potential in the treatment of Parkinson’s disease: current perspectives
by: Atashrazm F, et al.
Published: (2016) -
Roles of MET in Cancer Development and Treatment
Published: (2023)